BioNTech Navigates Q3 2025 with Increased Revenue and Strategic Oncology Progress
Mainz, Germany – BioNTech SE (Nasdaq: BNTX), the German biotechnology company, today announced its financial results for the third quarter of 2025, revealing a revenue of €1.5 billion, an increase from the prior year period. Despite this growth, the company reported a net loss of €28.7 million for the quarter. The announcement also highlighted significant advancements in its oncology strategy and an upward revision of its full-year revenue guidance. The results were published on November 3, 2025.
Financial Performance Overview
For the three months ending September 30, 2025, BioNTech's revenues reached €1,518.9 million, marking a notable increase compared to €1,244.8 million in the third quarter of 2024. This revenue growth was primarily driven by contributions from the company's collaboration with Bristol Myers Squibb (BMS), which included a $1.5 billion payment. In contrast to a net income of €198.1 million in Q3 2024, BioNTech recorded a net loss of €28.7 million, resulting in a basic and diluted loss per share of €0.12. Year-to-date revenues for the nine months ended September 30, 2025, stood at €1,962.5 million, with a year-to-date net loss of €831.1 million.
As of September 30, 2025, BioNTech maintained a strong financial position with cash, cash equivalents, and securities totaling €16,704.9 million. The company has also raised its full-year 2025 revenue guidance to a range of €2.6 billion to €2.8 billion, while simultaneously lowering its guidance for research and development (R&D), selling, general, and administrative (SG&A) expenses, and capital expenditures.
Advancements in Oncology Strategy
BioNTech provided a comprehensive update on its oncology strategy, emphasizing continued clinical execution with a focus on two pan-tumor programs. Key developments include:
- Encouraging interim Phase 2 data for pumitamig (BNT327/BMS986545), a bispecific antibody candidate, in extensive-stage small cell lung cancer (ES-SCLC). The data demonstrated anti-tumor activity and a manageable safety profile.
- Plans to initiate additional pivotal trials for pumitamig in first-line microsatellite stable colorectal cancer and first-line gastric cancer.
- Continued advancement of its diversified clinical pipeline, which includes mRNA immunotherapies and next-generation immunomodulators.
- Leveraging AI capabilities to enhance the discovery and development of personalized therapies.
The company's collaboration with Bristol Myers Squibb remains central to the development of pumitamig and other oncology initiatives. Additionally, BioNTech launched a variant-adapted COVID-19 vaccine for the 2025/2026 season, further diversifying its operational activities.
Leadership Commentary
Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech, commented on the progress in their oncology strategy, reiterating the objective to deliver transformative therapeutic options for patients. Ramón Zapata, Chief Financial Officer, highlighted the strategic value of the company's partnerships in boosting revenue guidance and optimizing the cost base for sustainable development.
5 Comments
ZmeeLove
Pumitamig's Phase 2 data is really encouraging. Breakthroughs like this are why I invest.
Comandante
BioNTech is making strides in diversifying its pipeline beyond COVID, which is a smart move. Still, converting these early-stage oncology successes into market-ready products is a long and expensive journey.
Muchacha
The progress with pumitamig in oncology is genuinely promising, offering new treatment avenues. However, the company's overall financial losses highlight the intense investment required for drug development.
BuggaBoom
Lowering R&D guidance while touting innovation? Sounds like they're cutting corners.
ZmeeLove
It's positive to see revenue growth driven by strategic partnerships like BMS, boosting their financial outlook. Yet, the reported net loss shows the challenge of balancing R&D spend with immediate profitability.